by Peter Ciszewski | Sep 6, 2017
David G. Birch, PhD, Chief Scientific and Executive Officer and Director of the Rose-Silverthorne Retinal Degenerations Laboratory, Retina Foundation of the Southwest discusses emerging treatment options for patients suffering from X-linked retinoschisis (XLRS)....
by Peter Ciszewski | Sep 5, 2017
Insmed announced top-line data from its Phase 3 CONVERT study. The global CONVERT study met its primary endpoint of culture conversion by Month 6 with statistical and clinical significance. The study demonstrated that the addition of ALIS to guideline-based therapy...
by Peter Ciszewski | Aug 28, 2017
With today’s $12 billion purchase of Santa Monica-based Kite Pharma, Gilead has not only validated the CAR-T industry, but also put a price on what the technology is worth. With their product likely to new approved by November, Kite has been recognized as an industry...
by Peter Ciszewski | Aug 27, 2017
David G. Birch, PhD, Chief Scientific and Executive Officer and Director of the Rose-Silverthorne Retinal Degenerations Laboratory, Retina Foundation of the Southwest discusses X-Linked Retinoschisis (XLRS). X-linked retinoschisis (XLRS) is an inherited early onset...
by Peter Ciszewski | Aug 15, 2017
Newron Pharmaceuticals is sponsoring a study to evaluate the burden of disease experienced by patients with Rett syndrome and their families. The announcement was made during the international 2016 Rettsyndrome.org Research Symposium, held in Itasca, Illinois, USA,...
